Wed, March 27, 2024

Eliana Merle Maintained (TERN) at Strong Buy with Decreased Target to $18 on, Mar 27th, 2024

Eliana Merle of UBS, Maintained "Terns Pharmaceuticals, Inc." (TERN) at Strong Buy with Decreased Target from $19 to $18 on, Mar 27th, 2024.

Eliana has made no other calls on TERN in the last 4 months.



There are 4 other peers that have a rating on TERN. Out of the 4 peers that are also analyzing TERN, 1 agrees with Eliana's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Ed Arce of "HC Wainwright & Co." Reiterated at Hold and Held Target at $5.5 on, Friday, March 15th, 2024


These are the ratings of the 3 analyists that currently disagree with Eliana


  • Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Decreased Target to $15 on, Monday, March 18th, 2024
  • Etzer Darout of "BMO Capital" Maintained at Buy with Increased Target to $19 on, Friday, March 15th, 2024
  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $10 on, Monday, November 27th, 2023